Free Trial

Atyr PHARMA 11/7/2024 Earnings Report

Atyr PHARMA logo
$3.61 -0.14 (-3.73%)
As of 01/17/2025 04:00 PM Eastern

Atyr PHARMA EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Atyr PHARMA Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.13 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atyr PHARMA Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Atyr PHARMA Earnings Headlines

Cantor Fitzgerald Estimates Atyr PHARMA FY2024 Earnings
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
aTyr Pharma appoints Eric Benevich to the company’s Board
See More Atyr PHARMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atyr PHARMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atyr PHARMA and other key companies, straight to your email.

About Atyr PHARMA

Atyr PHARMA (NASDAQ:ATYR), Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View Atyr PHARMA Profile

More Earnings Resources from MarketBeat